2Gruentizig A, Senning A, Siegenthaler W E. Nonoperative dilatation of coronary-artery stenosis: percutaneous transluminal balloon angioplasty[J]. New Engl J Med, 1979,301(2) :61-68.
3Anderson V H, Smalling R W, Serruys P W. Mechanical devices. In: Willerson JT, Cohn JN, editors. Cardiovascular Medicine[M]. 3rd edition. New York, Edinbergh, London: Churchill livingstone, 1996. 617-661.
4Bairn D S, Cutlip D E, Sharma S K, et al . Final results of Balloon vs Optimal Athereetomy Trial (BOAT) [J]. Circulation, 1998, 97(4):322-331.
5Bauters C, Meurice T, Hamon M, tt al. Mechanism and prevention of restenosis: from experimental models to clinical practice[J]. Cardiovasc Res, 1996, 31 (6) :835-846.
6Luscher T F, Barton M. Endothelins and endothelin receptor antagonists: therapeutic considerations for a novel class of cardiovascular drugs [J]. Circulation, 2000, 102 (19) : 2434-2440.
7Jeng A Y, Mulder P, Kwan A L, et al. Nonpeptidic endothelin-converting enzyme inhibitors and their potential therapeutic applications[J]. Can J Physiol Pharmacol, 2002,80(5) : 440-449.
8Tahara A, Kohno M, Yanagi S, et al. Circulating immunoreactive endothelin in patients undergoing percutaneous transluminal coronary angioplasty[J]. Metabolism, 1991, 40(12) : 1235-1237.
9Douglas S A, Louden C, Vichery-Clark L M, et al . A role for endogeneous endothelin-1 in neointimal formation after rat carotid artery balloon angioplasty. Protective effects of the novel nonpeptide endothelin receptor antagonist SB 209670 [J]. Circ Res, 1994, 75(1) :190-197.
10Wang X, Douglas S A, Louden C, a al. Expression of endothelin-1, endothelin-3, endothe].in-converting enzyme-1, and endothelin-A and endothelin-B receptor mRNA after angioplasty-induced neointimal formation in the rat[J]. Circ Res, 1996, 78(2)2322-328.
